ARNA Press Release tomorrow at 5:30 am Pacific time

Now that the press release is issued, I can mention the name of the company I've been raving about. I didn't want to invite scrutiny from regulators about pumping and dumping. Some of my friends and family have known about this speculative play for several weeks and months. I'm glad to say a few acted upon it. It was entirely their decision and they performed their own due diligence.

The timing of the conference call, 5:30 am Pacific time, is significant. It is pre-market opening, which suggests good results from their Phase III clinical trials. A positive announcement post-market close, leaves market manipulators plenty of time that evening and the next morning to manipulate the stock price, punishing shareholders in after hours training. Regarding the timing of announcements of pivotal trials: negative announcements are usually scheduled after market close, while positive announcements usually occur before market opening.

In fact, market manipulation is why this stock stayed at $4 for many days in March. The shorts drove the share prices down, making a profit on the share price decline. Shorting also benefited institutions betting on the share price rising, as they get to buy shares at a lower price. That's why it's common to see analysts downgrade stocks before an important announcement, which is exactly what happened with Arena. Market manipulation is nefarious and illegal, and these individuals and institutions should be bird-dogged and reported to the SEC. However, as an individual investor, and as one who acknowledge sometimes the system is rigged, one should adjust one's investment strategies accordingly. In my case, it allowed me multiple entry points to accumulate shares, because investor sentiment was negative, and I had conviction that Arena was on to something big--I had confidence that Lorcaserin is a game-changer.

Friday's close was $4.50. After positive results, I expect the market to gap up before tomorrow's market opening in the teens, with high volatility throughout the week, amid price spikes for the next few days. I will avoid trading as orders will be difficult to fill--I will just monitor it and watch the shorts scramble, while the share price soars.

Investing is risky and investing in biotech stocks even riskier. Do your own due diligence and consult your financial advisor, altho 99% of them are behind the learning curve. Proceed with caution, and good luck to all.

Disclosure: I own shares in ARNA underlying shares and ARNA call options.


http://finance.yahoo.com/news/Arena-Pharmaceuticals-to-Host-prnews-14777035.html

SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - News) today announced it will hold a conference call and webcast on Monday, March 30, 2009 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management. Jack Lief, President and Chief Executive Officer, Dominic P. Behan, Ph.D., Senior Vice President and Chief Scientific Officer, William R. Shanahan, M.D., Vice President and Chief Medical Officer, and Christen M. Anderson, M.D., Ph.D., Vice President, Clinical Development, will host the conference call.

The conference call may be accessed by dialing 877.874.1565 for domestic callers and 719.325.4758 for international callers. Please specify to the operator that you would like to join the "Lorcaserin BLOOM Trial Results" conference call. The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.